JP2025519127A - 疼痛の処置で使用されるペプチド及び方法 - Google Patents

疼痛の処置で使用されるペプチド及び方法 Download PDF

Info

Publication number
JP2025519127A
JP2025519127A JP2024569387A JP2024569387A JP2025519127A JP 2025519127 A JP2025519127 A JP 2025519127A JP 2024569387 A JP2024569387 A JP 2024569387A JP 2024569387 A JP2024569387 A JP 2024569387A JP 2025519127 A JP2025519127 A JP 2025519127A
Authority
JP
Japan
Prior art keywords
peptide
seq
pain
peptides
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024569387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025519127A5 (cg-RX-API-DMAC7.html
Inventor
アブデラジズ・モクリッチ
ステファーヌ・ガイヤール
Original Assignee
タファルジー・セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タファルジー・セラピューティクス filed Critical タファルジー・セラピューティクス
Publication of JP2025519127A publication Critical patent/JP2025519127A/ja
Publication of JP2025519127A5 publication Critical patent/JP2025519127A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024569387A 2022-05-25 2023-05-25 疼痛の処置で使用されるペプチド及び方法 Pending JP2025519127A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305773.8 2022-05-25
EP22305773 2022-05-25
PCT/EP2023/064091 WO2023227731A1 (en) 2022-05-25 2023-05-25 Peptides and methods for use in treating pain

Publications (2)

Publication Number Publication Date
JP2025519127A true JP2025519127A (ja) 2025-06-24
JP2025519127A5 JP2025519127A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=81975215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024569387A Pending JP2025519127A (ja) 2022-05-25 2023-05-25 疼痛の処置で使用されるペプチド及び方法

Country Status (12)

Country Link
US (1) US20250213654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025519127A (cg-RX-API-DMAC7.html)
KR (1) KR20250017221A (cg-RX-API-DMAC7.html)
CN (1) CN119730868A (cg-RX-API-DMAC7.html)
AR (1) AR129441A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023275937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253053A1 (cg-RX-API-DMAC7.html)
IL (1) IL317048A (cg-RX-API-DMAC7.html)
MX (1) MX2024014419A (cg-RX-API-DMAC7.html)
TW (1) TW202409064A (cg-RX-API-DMAC7.html)
WO (1) WO2023227731A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
CN103382220A (zh) * 2012-05-03 2013-11-06 北京大学 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
AR129441A1 (es) 2024-08-28
MX2024014419A (es) 2024-12-06
IL317048A (en) 2025-01-01
AU2023275937A1 (en) 2024-12-12
KR20250017221A (ko) 2025-02-04
CA3253053A1 (en) 2023-11-30
CN119730868A (zh) 2025-03-28
TW202409064A (zh) 2024-03-01
WO2023227731A1 (en) 2023-11-30
EP4531886A1 (en) 2025-04-09
US20250213654A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
US20250221936A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
US20090280103A1 (en) Regulation of muscle repair
US20250213654A1 (en) Peptides and methods for use in treating pain
JP6312436B2 (ja) ネプリライシンの発現および活性を増大させるための方法および医薬組成物
JP7097070B2 (ja) クロライドチャネルの標的発現及びその使用方法
Del Bufalo et al. Alpha9Alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain
KR101749138B1 (ko) 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
US20250051395A1 (en) Peptides and methods for use in treating pain
CA3106078A1 (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
JP7380670B2 (ja) Igf-1-暗号化dna作製物及びhgf-暗号化dna作製物を用いた神経病症治療
JP4581115B2 (ja) そう痒性皮膚疾患の治療又は予防剤
EP2919816B1 (en) Combination treatment for amyotrophic lateral sclerosis (als)
CN109069669A (zh) 载体
JP2019070001A (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
OA22072A (en) Peptides and methods for use in treating pain.
OA22140A (en) Peptides and methods for use in treating pain.
KR20130122927A (ko) Dkk2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
Xiao Genome Editing to Abrogate Muscle Atrophy
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
JP2026501737A (ja) レトロ-aav、および神経変性疾患の処置における使用
WO2020022518A1 (ja) 筋萎縮性側索硬化症を含む神経疾患の予防剤及び/又は治療剤
CA3258210A1 (en) Gene therapy at VAA for the treatment of a nervous system disease
WO2024155689A1 (en) Compounds and methods for inhibiting type-iii receptor tyrosine kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260507